Literature DB >> 32205724

Quarterly screening optimizes detection of sexually transmitted infections when prescribing HIV preexposure prophylaxis.

Eric C Tang1, Eric Vittinghoff2, Susan S Philip2,3, Susanne Doblecki-Lewis4, Oliver Bacon2,3, Wairimu Chege5, Megan E Coleman6, Richard Elion7, Susan Buchbinder2,3, Michael A Kolber4, Albert Y Liu2,3, Stephanie E Cohen2,3.   

Abstract

OBJECTIVE: The optimal screening frequency of sexually transmitted infections (STIs) for MSM and transgender women (TGW) on HIV pre-exposure prophylaxis (PrEP) is unclear, with present guidelines recommending screening every 3-6 months. We aimed to determine the number of STIs for which treatment would have been delayed without quarterly screening.
DESIGN: The US PrEP Demonstration Project was a prospective, open-label cohort study that evaluated PrEP delivery in STI clinics in San Francisco and Miami, and a community health center in Washington, DC. In all, 557 HIV-uninfected MSM and TGW were offered up to 48 weeks of PrEP and screened quarterly for STIs.
METHODS: The proportion of gonorrhea, chlamydia, and syphilis infections for which treatment would have been delayed had screening been conducted every 6 versus every 3 months was determined by taking the number of asymptomatic STIs at weeks 12 and 36 divided by the total number of infections during the study follow-up period for each STI.
RESULTS: Among the participants, 50.9% had an STI during follow-up. If screening had been conducted only semiannually or based on symptoms, identification of 34.3% of gonorrhea, 40.0% of chlamydia, and 20.4% of syphilis infections would have been delayed by up to 3 months. The vast majority of participants (89.2%) with asymptomatic STIs reported condomless anal sex and had a mean of 8.1 partners between quarterly visits.
CONCLUSIONS: Quarterly STI screening among MSM on PrEP could prevent a substantial number of partners from being exposed to asymptomatic STIs, and decrease transmission.

Entities:  

Mesh:

Year:  2020        PMID: 32205724     DOI: 10.1097/QAD.0000000000002522

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  2 in total

1.  Beyond HIV prevention: Additional individual and community-level benefits of PrEP among Latino gay and bisexual men.

Authors:  Ronald A Brooks; Omar Nieto; Martin Santillan; Amanda Landrian; Anne E Fehrenbacher; Alejandra Cabral
Journal:  PLoS One       Date:  2022-06-13       Impact factor: 3.752

2.  Non-itchy, Nodular Intermittently Healing Persistent Lesions on the Neck, Arms and Gluteus: A Quiz.

Authors:  Teodora Pumnea; Zeno Fiocco; Benjamin M Clanner-Engelshofen; Michael Flaig; Lars E French; Markus Reinholz
Journal:  Acta Derm Venereol       Date:  2021-04-15       Impact factor: 3.875

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.